Decoy Therapeutics Announces 2026 Annual Meeting of Stockholders

Decoy Therapeutics Inc. has filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual Meeting of Stockholders, scheduled for July 14, 2026, to be held via live audio webcast. Key items on the agenda include the election of three Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board of Directors recommends a vote in favor of all proposed items. Stockholders of record as of May 22, 2026, are eligible to vote.